Drug Discovery & Development | Pfizer Inc. : Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of ... 4-traders (press release) Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant. The primary ... Pfizer Inc. (NYSE:PFE) | Pfizer Announces Top-Line Results Of Phase 3B/4 ... Pfizer says organ transplant drug fails in study Pfizer's Rapamune Doesn't Meet Primary Endpoint in Study of Kidney Transplant ... |
